# Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

> **NCT04854889** · PHASE2 · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 3 (actual)

## Conditions studied

- Refractory Aplastic Anemia

## Interventions

- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT04854889
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-22
- **Primary completion:** 2022-07-26
- **Final completion:** 2022-08-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Not achieve the desired effect
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854889, "Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04854889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*